Latest news

  • ASIT biotech gp-ASIT+TM Phase III trial in grass pollen allergy did not meet the primary endpoint Monday, 25 November 2019
  • Declaration of dissociation of a member of the Board of Directors at the General Assembly Friday, 15 November 2019
  • ASIT biotech mode of action study of gp-ASIT+™ for grass pollen allergy published in The Journal of Allergy and Clinical Immunology (JACI) Thursday, 17 October 2019
  • All ASIT news


Share Price :
0.294 EUR
Previous close: 0.297 EUR


  • JP Morgan, San Francisco : January 13th 2020 - 16 January 2020

All ASIT events